Discovery of a 2′-α-Fluoro-2′-β- C -(fluoromethyl) Purine Nucleotide Prodrug as a Potential Oral Anti-SARS-CoV-2 Agent
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02769 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Lan Liang und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, NMPA Key Laboratory for Research and Evaluation of Innovative Drug, School of Chemistry…. Hauptthemen laut MEDLINE: Prodrugs, Antiviral Agents, SARS-CoV-2, COVID-19 Drug Treatment. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Natural Science Foundation of Henan Province, Central Plains Scholars and Scientists Studio Fund, National Natural Science Foundation of China.
Abstract (Originalsprache)
A novel 2'-α-fluoro-2'-β-C-(fluoromethyl) purine nucleoside phosphoramidate prodrug 15 has been designed and synthesized to treat SARS-CoV-2 infection. The SARS-CoV-2 central replication transcription complex (C-RTC, nsp12-nsp7-nsp82) catalyzed in vitro RNA synthesis was effectively inhibited by the corresponding bioactive nucleoside triphosphate (13-TP). The cryo-electron microscopy structure of the C-RTC:13-TP complex was also determined. Compound 15 exhibited potent in vitro antiviral activity against the SARS-CoV-2 20SF107 strain (EC50 = 0.56 ± 0.06 μM) and the Omicron BA.5 variant (EC50 = 0.96 ± 0.23 μM) with low cytotoxicity. Furthermore, it was well tolerated in rats at doses of up to 2000 mg/kg, and a single oral dose of this prodrug at 40 mg/kg led to high levels of 13-TP in the target organ lungs of rats with a long half-life. These findings support the further development of compound 15 as an orally available antiviral agent for the treatment of SARS-CoV-2 infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, NMPA Key Laboratory for Research and Evaluation of Innovative Drug, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, Henan 45…
- State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, College of Chemistry, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
- State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences and College of Pharmacy, Nankai University, Tianjin 300071, China.
- MOE Key Laboratory of Protein Science, School of Medicine, Tsinghua University, Beijing 100084, China.
- Henan Key Laboratory for Pharmacology of Liver Diseases, Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450052, China.
ORCID-Profile: Bo Zhu, Wenquan Yu, Junbiao Chang
Förderung
- Natural Science Foundation of Henan Province
- Central Plains Scholars and Scientists Studio Fund
- National Natural Science Foundation of China
- Henan Province
Zitieren
APA
Liang, L., Meng, Y., Chang, X., Li, E., Huang, Y., Yan, L., Lou, Z., Peng, Y., Zhu, B., Yu, W., & Chang, J. (2025). Discovery of a 2′-α-Fluoro-2′-β- C -(fluoromethyl) Purine Nucleotide Prodrug as a Potential Oral Anti-SARS-CoV-2 Agent. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02769
Vancouver
Liang L, Meng Y, Chang X, Li E, Huang Y, Yan L, et al. Discovery of a 2′-α-Fluoro-2′-β- C -(fluoromethyl) Purine Nucleotide Prodrug as a Potential Oral Anti-SARS-CoV-2 Agent. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02769
BibTeX
@article{Liang2025,
author = {Liang, Lan and Meng, Yonggang and Chang, Xiaoyu and Li, Ertong and Huang, Yucen and Yan, Liming and Lou, Zhiyong and Peng, Youmei and Zhu, Bo and Yu, Wenquan and Chang, Junbiao},
title = {Discovery of a 2′-α-Fluoro-2′-β- C -(fluoromethyl) Purine Nucleotide Prodrug as a Potential Oral Anti-SARS-CoV-2 Agent},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02769}
}
EUVIMED